Articles tagged "Induction therapy"

2015 American Transplant Congress
Induction Avoidance in 2-Haplotype-Matched White Living Kidney Transplantation
Z. Brifkani,¹ T. Alhamad,¹ T. Horwedel,² R. Delos Santos,¹ T. Maw,¹ D. Brennan.¹
¹Transplant Nephrology, Washington University in St. Louis, St. Louis, MO; ²Barnes Jewish Hospital, St. Louis, MO.
Background: We hypothesize that 2-haplotype matched white living kidney transplant recipients carry a low immunologic risk for rejection, and therefore do not give induction therapy…
2015 American Transplant Congress
Pancreas Transplantation Immunosuppression Induction With Rabbit Antithymocyte Globulin +/- Rituximab and Early Steroid Withdrawal: Experience With >500 Recipients
J. Fridell,¹ R. Mangus,¹ J. Chen,² M. Mujtaba,³ T. Taber,³ M. Goble,¹ J. Powelson.¹
¹Surgery, Indiana University School of Medicine, Indianapolis, IN; ²Pharmacy, Indiana University School of Medicine, Indianapolis, IN; ³Medicine, Indiana University School of Medicine, Indianapolis, IN.
T-cell depleting antibody induction, often combined with steroid withdrawal, has become standard practice for pancreas transplantation. In this study, outcomes of >500 pancreas transplants using…
2015 American Transplant Congress
Immune-Mediated Injury in Kidney Transplant Recipients Treated With Alemtuzumab Induction and a Steroid Avoidance Protocol
R. Sapir-Pichhadze, T. Mahbub, C. Saw, D. Baran.
McGill University Health Centre, Montreal, Canada.
Study purpose: We evaluated short-term clinical and immunological outcomes of kidney transplant recipients who received alemtuzumab induction and a steroid-avoidance protocol.Methods: This is a retrospective…
2015 American Transplant Congress
The Impact of Alemtuzumab and Basiliximab Induction On Patient and Graft Survival in Single Lung Transplant Recipients
Y. Furuya,¹ S. Jayarajan,² S. Taghavi,² V. Ambur,² F. Cordova,³ N. Patel,³ Y. Toyoda.⁴
¹Internal Medicine, Temple University Hospital, Philadelphia, PA; ²Surgery, Temple University Hospital, Philadelphia, PA; ³Pulmonary & Critical Care, Temple University Hospital, Philadelphia, PA; ⁴Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.
PurposeTo evaluate the impact of alemtuzumab, basiliximab and no induction therapy on patient survival and chronic rejection.Methods3242 adult single lung transplantation from 2006 to 2013…
2015 American Transplant Congress
Optimal Induction Therapy (IT) in Pancreas After Kidney Transplantation (PAK) According to Type of Kidney (kd) Donor and Patient Risk – A Registry Analysis
R. Gruessner,¹ A. Gruessner.²
¹University of Arizona, Tucson, AZ; ²University of Arizona, Tucson, AZ.
Purpose: Best IT in PAK recipients (rec) according to type of kd donor (LD vs. DD) and rec risk has not been determined.Methods: Using the…
2015 American Transplant Congress
Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe
J. Casale, J. Fleming, D. Taber, C. Staino, K. Boyle, K. Covert, N. Pilch, H. Meadows, C. Mardis, K. Chavin, C. Bratton, J. McGillicuddy, P. Baliga.
MUSC, Charleston, SC.
Background: The effectiveness and safety of induction with basiliximab (IL2RA) in sensitized kidney transplant recipients is not clearly established. The aim of this study was…
2015 American Transplant Congress
The Association of Basiliximab and Antithymocyte Globulin Induction With Delayed Graft Function
D. Felix,¹ B. Astor,² D. Hager,¹ A. Djamali.²
¹Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI; ²Department of Medicine - Division of Nephrology, University of Wisconsin Hospital and Clinics, Madison, WI.
The impact of selection of induction immunosuppression agent on incidence of delayed graft function (DGF) remains unclear. A total of 1,980 deceased donor kidney transplant…